云顶新耀领衔,中国mRNA肿瘤疫苗军团崛起

Ofweek光电信息网
25 Mar

说到做到。3月6日,云顶新耀宣告个性化mRNA肿瘤治疗性疫苗EVM16完成首例患者给药,与此同时预告:通用型现货肿瘤治疗性疫苗EVM14在2月份已向FDA申报临床。3月24日,云顶新耀便官宣,EVM14获FDA IND批准,成为其首款自研进入全球临床的mRNA肿瘤疫苗。自主研发的mRNA肿瘤管线持续落地,云顶新耀堪称中国药企效率标杆。这也印证了其自主研发能力,且体系与全球监管框架的高度适配,标志着...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10